<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687258</url>
  </required_header>
  <id_info>
    <org_study_id>Vit E-Rif01-1</org_study_id>
    <nct_id>NCT00687258</nct_id>
  </id_info>
  <brief_title>Evaluation Of A New Vitamin E-Bonded Membrane On Anemia And Oxidative Stress In End-Stage Renal Disease Patients</brief_title>
  <acronym>Vi-E</acronym>
  <official_title>Evaluation Of The Impact Of A New Synthetic Vitamin E-Bonded Membrane On The Anemia And Oxidative Stress In End-Stage Renal Disease (ESRD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A. Manzoni Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>A. Manzoni Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this longitudinal study is to point out the effect of VitabranE on the&#xD;
      ESA resistance and on the anemia observed in HD patients undergoing EPO maintenance therapy.&#xD;
&#xD;
      As a secondary purpose we will consider the effect of VitabranE on inflammation and oxidative&#xD;
      stress parameters as a function of the changes observed in the anemia parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim&#xD;
&#xD;
      The aim of this pilot randomized study is to verify whether the addition of vitamin E&#xD;
      alpha-tocopherol to the blood-side layer of a synthetic polysulfone dialyser membrane has a&#xD;
      clinical advantage in terms of ESA responsiveness and, consequently, the anemic status of&#xD;
      hemodialysed patients.&#xD;
&#xD;
      Patients&#xD;
&#xD;
      Patients of both genders aged more than 18 years will be considered eligible for the study if&#xD;
      they had been receiving bicarbonate hemodialysis treatment for at least six months and stable&#xD;
      ESA therapy for at least three months, and had adequate iron stores (ferritin levels &gt;200&#xD;
      ng/ml and transferrin saturation &gt;20%). Patients with haemoglobinopathies, sickle cell&#xD;
      anemia, thalassemia or malignancies will be excluded, as were those who had experienced&#xD;
      infection, vascular access thrombosis, stroke, myocardial infarction, heavy blood loss, major&#xD;
      surgery or blood transfusion in the previous three months.&#xD;
&#xD;
      Study design&#xD;
&#xD;
      This is an 8-month, controlled and randomised study of two parallel groups; after giving&#xD;
      their informed consent, the enrolled patients will be randomly assigned to the Vi-E&#xD;
      experimental treatment (polysulfone dialyser with vitamin E alpha-tocopherol) or the PS&#xD;
      control treatment (polysulfone dialyser without vitamin E alpha-tocopherol).&#xD;
&#xD;
      Clinical data&#xD;
&#xD;
      The dialyser will be randomly assigned at the beginning of the study, and pre and&#xD;
      end-dialysis body weight, blood pressure and heart rate will be recorded at baseline and&#xD;
      every two months. Dialysis prescription will not change during the study. All of the drugs&#xD;
      administered during each dialysis session will be recorded, as all of the prescribed&#xD;
      inter-dialysis therapies.&#xD;
&#xD;
      Laboratory data&#xD;
&#xD;
      Hemoglobin, serum albumin and plasma high-sensitivity C reactive protein levels (ELISA) will&#xD;
      be recorded at baseline and every other month, together with nutritional and inflammation&#xD;
      indices. Iron status will be evaluated on the basis of transferrin saturation and plasma&#xD;
      ferritin levels. Reticulocytes and PTH levels will be also recorded. Equilibrated Kt/V will&#xD;
      be calculated in order to estimate the dialysis dose of low molecular weight uraemic toxins,&#xD;
      and the appearance of urea nitrogen will be calculated in order to estimate daily protein&#xD;
      intake.&#xD;
&#xD;
      Plasma alpha-tocopherol and gamma tocopherol levels will be determined by means of&#xD;
      reverse-phase HPLC analysis; total antioxidant capacity (TAC) will be determined using the&#xD;
      ferric reducing-antioxidant power and advanced glycation end-products will be detected using&#xD;
      total fluorescence at 335/385 Ex/Em. Advanced oxidation protein products, carbonyl products,&#xD;
      erythrocyte creatine and interleukin 6 will be also determined.&#xD;
&#xD;
      Main response variable&#xD;
&#xD;
      The primary outcome measure will be the ESA resistance index, a combined variable calculated&#xD;
      by dividing the weekly ESA dose by haemoglobin level and end-dialysis body weight.&#xD;
&#xD;
      Sample size&#xD;
&#xD;
      Given the pilot nature of the study, it is estimated that a sample of twenty patients (ten&#xD;
      patients per group) will be sufficient to provide reasonable control over random variations&#xD;
      in ESA resistance.&#xD;
&#xD;
      Statistical analysis&#xD;
&#xD;
      The data will be described using median values and interquartile ranges based on 25th and&#xD;
      75th percentiles for the distributed continuous variables. The baseline distribution of the&#xD;
      continuous and categorical variables by group will be investigated using the Mann-Whitney and&#xD;
      Chi-squared tests as appropriate.&#xD;
&#xD;
      The follow-up data will be analyzed using analysis of variance for repeated measures in order&#xD;
      to test the possible differences in ESA resistance over time between the two groups.&#xD;
&#xD;
      A secondary analysis will be made by adding the values of some baseline covariates in order&#xD;
      to identify predictors associated with ESA resistance. In order to reduce over-parameterizing&#xD;
      the model, the explored covariates will be grouped in two hierarchical steps:&#xD;
&#xD;
        1. Biocompatibility of the previous membrane (categorical), iron status (transferrin&#xD;
           saturation and ferritin), nutrition (albumin), intact PTH, inflammation (high-&#xD;
           sensitivity C reactive protein);&#xD;
&#xD;
        2. Add some markers of oxidative stress (TAC, alpha- and gamma-TOC, carbonyl products,&#xD;
           AOPP, AGEs and erythrocyte creatine) The effect of the experimental treatment over time&#xD;
           will be tested by means of group interaction, with this hierarchical approach.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure will be the ESA resistance index, a combined variable calculated by dividing the weekly ESA dose by haemoglobin level and end-dialysis body weight.</measure>
    <time_frame>every other month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory status (CRP and IL-6) and oxidative stress markers (Vitamin E levels, TAC, Protein carbonyls and AOPP, AGEs).</measure>
    <time_frame>every other month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VitabranE ViE: Vitamin E-bonded polysulfone dialyzer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>APS-U (Asahi Polysulfone APS): Polysulfone dialyzer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VitabranE ViE</intervention_name>
    <description>Polysulfone dialyser with vitamin E alpha-tocopherol</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Vitamin E-bonded polysulfone dialyzer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients, aged â‰¥ 18, stabilized on BHD for at least 6 months.&#xD;
&#xD;
          2. Clinical stability during the last 3 months.&#xD;
&#xD;
          3. Serum Ferritin &gt; 200 mg/L and Transferrin saturation &gt;30%.&#xD;
&#xD;
          4. Maintenance therapy with epoetin alfa/beta or darbepoetin alfa.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. One of the following condition in the last 3 months :&#xD;
&#xD;
               -  acute infection&#xD;
&#xD;
               -  vascular access thrombosis&#xD;
&#xD;
               -  ictus cerebri&#xD;
&#xD;
               -  myocardial stroke&#xD;
&#xD;
               -  haemorrhage&#xD;
&#xD;
               -  major surgery&#xD;
&#xD;
               -  haemo-transfusion&#xD;
&#xD;
          2. Haemoglobinopaty, sickle cell anemia, familial erythroblastic anemia and any other&#xD;
             haematological disorder interfering with the aim of the study&#xD;
&#xD;
          3. Malignancy&#xD;
&#xD;
          4. Participation to other studies or use of EPO analogues not yet commercialized&#xD;
&#xD;
          5. pharmacological dosage administration of antioxidant supplements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Locatelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology and Dialysis Department - A. Manzoni Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alessandro Manzoni Hospital, Nephrology and Dialysis Department</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Andrulli S, Di Filippo S, Manzoni C, Stefanelli L, Floridi A, Galli F, Locatelli F. Effect of synthetic vitamin E-bonded membrane on responsiveness to erythropoiesis-stimulating agents in hemodialysis patients: a pilot study. Nephron Clin Pract. 2010;115(1):c82-9. doi: 10.1159/000294281. Epub 2010 Mar 8.</citation>
    <PMID>20215781</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>A. Manzoni Hospital</investigator_affiliation>
    <investigator_full_name>Simeone Andrulli, MD</investigator_full_name>
    <investigator_title>Simeone Andrulli, MD</investigator_title>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>dialyser membrane</keyword>
  <keyword>Vitamin E</keyword>
  <keyword>Erythropoietin responsiveness</keyword>
  <keyword>Erythropoietin resistance</keyword>
  <keyword>hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin E</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

